Can you live 20 years after prostate removal?

What the numbers actually say

For men diagnosed with localised prostate cancer who undergo radical prostatectomy, the published long-term outcomes are reassuring. Across multiple large institutional series and population datasets, 15-year cancer-specific survival exceeds 90% in low- and intermediate-risk disease, and 20-year overall survival is the norm rather than the exception in men diagnosed under age 65.^[1] The Johns Hopkins series, with median follow-up beyond 15 years, has been particularly influential in establishing this picture.^[2]

The picture changes with risk group. Men with high-risk localised disease at the time of surgery — typically defined by Gleason score 8 or above, PSA above 20 ng/mL, or extensive extracapsular extension — have lower long-term cancer-specific survival, though long-term outcomes have improved meaningfully with the addition of radiation and hormonal therapy when indicated post-surgery.^[3]

This is the framework we will work through. The first one is largely fixed by the time you read this article. The second is partly out of your control — biology is biology — but is detected by a simple blood test that you should never skip. The third is where modern nuclear medicine has fundamentally changed the picture in the last decade.

The PSA blood test — the most important number you'll ever track

After radical prostatectomy, serum PSA should fall to undetectable within six weeks. The prostate is the primary source of PSA in the body, and once it has been removed, levels typically settle below 0.1 ng/mL. This undetectable PSA is the surveillance baseline. As long as PSA stays there, the surgery has cleared the cancer that was visible at the time, and life moves on.

The schedule of PSA monitoring varies slightly between centres but generally follows this pattern: every three months for the first year, every six months for years two and three, then annually for life. The annual schedule is not optional. There are men in their seventies and eighties who attend our clinic for advanced prostate cancer where the warning sign — a PSA that started rising at year ten or year fifteen — was missed because the annual blood test was quietly dropped.

What is biochemical recurrence?

Biochemical recurrence is a rise in PSA after surgery that signals some prostate cancer cells are still present somewhere in the body. The standard definition is PSA reaching 0.2 ng/mL on two consecutive measurements. Roughly 25–35% of men experience biochemical recurrence within ten years of surgery, with the highest risk in the first three to five years.^[4]

It is important to understand what biochemical recurrence does and does not mean. It does not mean cancer has spread to a critical organ. It does not mean treatment has failed. It does not mean a foreshortened life. What it means, specifically, is that the PSA blood test is detecting prostate cancer cells somewhere — and the urgent next step is to identify where those cells are, because location determines what can be done.

Where nuclear medicine changes the picture — PSMA PET

Until about a decade ago, the gap between "PSA is rising" and "we can see where" was a real clinical problem. Conventional CT scans and bone scans only detect prostate cancer recurrence reliably at relatively high PSA levels, by which point treatment options have often narrowed. Many men spent years on hormonal therapy without anyone knowing exactly where the cancer was.

PSMA PET — Prostate-Specific Membrane Antigen positron emission tomography — has fundamentally changed this. PSMA is a protein expressed on the surface of prostate cancer cells. The imaging tracer (most commonly 68Ga-PSMA-11 or ¹⁸F-PSMA-1007) binds to PSMA and emits a signal that PET cameras detect. The result is the most sensitive imaging test currently available for detecting prostate cancer recurrence at low PSA levels — well below the threshold at which conventional imaging starts to find disease.^[5]

For men with biochemical recurrence after prostatectomy, PSMA PET typically becomes useful at a PSA threshold around 0.2–0.5 ng/mL. The detection rate climbs steadily with rising PSA. At PSA above 1 ng/mL, PSMA PET locates the recurrence in the majority of cases. The clinical question shifts from "is there cancer somewhere?" (yes — the PSA tells us so) to "where exactly is it, and what can we do about it?"

What treatment looks like, by location of recurrence

The treatment plan for biochemical recurrence depends almost entirely on where the cancer is found. PSMA PET makes this question answerable with precision that did not exist a decade ago. Broadly, recurrences fall into four patterns:

• Local recurrence in the prostate bed — salvage radiation therapy is often curative when delivered early, before disease has spread further
• Pelvic lymph node recurrence — typically managed with extended-field radiation plus a defined course of hormone therapy; long-term remission is achievable in many patients
• Limited (oligometastatic) recurrence — a small number of metastases visible on PSMA PET — increasingly treated with targeted radiation to each lesion, sometimes preserving freedom from systemic hormone therapy for years
• Widespread metastatic recurrence — managed with hormone therapy as first line, with later options including chemotherapy, novel hormonal agents, and PSMA radioligand therapies (Lu-177 PSMA or Ac-225 PSMA) for selected patients whose disease has progressed on standard treatments

What this list illustrates: a man whose biochemical recurrence is detected and located early has a very different treatment trajectory from one whose recurrence is detected late and only at the metastatic stage. The two men can have the same surgery, the same Gleason score, the same year of diagnosis — and end up with different long-term outcomes because the recurrence was found at PSA 0.4 in one case and PSA 8 in the other.

The life part of long-term survival

Statistics about 20-year survival are useful, but they are not what most men actually want to know. What men want to know is: will I be functional, present, and well in those twenty years? The honest answer is that most men do well — but the conversation about quality of life after prostate removal is often handled less openly than the conversation about cure.

Two areas are worth raising explicitly with your urologist before, and after, surgery: urinary continence and sexual function. Modern surgical techniques — robotic-assisted prostatectomy with nerve-sparing where the cancer permits — have improved both substantially compared with twenty years ago. But neither is uniformly preserved, and both deserve frank discussion. Men who attend pelvic floor physiotherapy in the months after surgery have measurably better continence outcomes. Men who discuss sexual function openly with their care team have access to a wider range of options when recovery is incomplete.

The third area is more diffuse: the psychological adjustment of carrying a cancer history for the next two decades. The annual PSA test is not a small thing for men who have been through prostate cancer surgery. Most men adjust. Some need support. Speaking openly about it is a sensible thing to do — with family, with the urology team, with peers, and where helpful, with a counsellor experienced in cancer survivorship.

A closing thought

Twenty-year survival after prostate removal is, for most men with localised disease, the realistic expectation rather than the optimistic best case. The men who do best in our experience are not the men with the simplest disease at the start. They are the men who attend their PSA tests every year without fail, who take biochemical recurrence seriously when it happens but do not panic, who get high-quality imaging early when PSA starts to rise, and who work with a multidisciplinary team that understands the full menu of options — from salvage radiation, to targeted lesional therapy, to PSMA radioligand therapy when the time comes.

If you are reading this in the period before surgery, the practical advice is to go in well-informed, ask about quality-of-life outcomes as carefully as you ask about cancer outcomes, and commit to the post-surgical surveillance schedule. If you are reading it years after surgery, with a PSA that has begun to rise, the practical advice is simpler: do not wait. Get a high-quality PSMA PET, get an expert read, and make a treatment plan based on what the imaging actually shows. The early-recurrence patients we see in our clinic are the ones who do well over the next ten years. We would rather see you at PSA 0.4 than at PSA 4.